Journal of global antimicrobial resistance · 2026
Ceftazidime-avibactam-based regimens for the treatment of central nervous system infections caused by carbapenem-resistant Klebsiella pneumoniae in a paediatric patient.
СтатьяКлинический случайНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
He Liming, Li Wanzhen, Chen Weiming, Wang Yixue, Liu Xiaofen, Fu Pan, Wang Chuanqing, Zhang Junqi, Lu Guoping, Yan Gangfeng, Zhang Jing
Аннотация
OBJECTIVE: Carbapenem-resistant Klebsiella pneumoniae (CRKP) central nervous system (CNS) infections are difficult to treat in children because effective and safe therapeutic options are limited. We report a paediatric case of CRKP meningitis successfully treated with ceftazidime-avibactam (CZA) combination with intraventricular polymyxin B (PMB).
METHODS: A 9-y-old child with severe traumatic brain injury and multiple prior neurosurgical procedures developed CRKP meningitis. After pathogen identification, antimicrobial therapy was switched to CZA plus intraventricular PMB, and the ventriculoperitoneal shunt was externalized. Clinical outcomes, cerebrospinal fluid (CSF) parameters, microbiological clearance, and plasma and CSF concentration of CZA were monitored during treatment.
RESULTS: After CRKP was identified, therapy was adjusted to CZA (62.5 mg/kg every 8 h, administered as a 2-h infusion) plus intraventricular PMB based on susceptibility results. Fever resolved within 3 d of CZA initiation. CSF cultures became negative, and CSF parameters gradually normalized. Neurological status improved, and the patient was transferred to a rehabilitation facility. Pharmacokinetic analysis showed blood-brain barrier penetration rates of 19.4% for ceftazidime and 29.9% for avibactam.
CONCLUSIONS: This report adds to the limited pharmacokinetic/pharmacodynamic (PK/PD) evidence for ceftazidime-avibactam in paediatric CNS infections. It also supports the potential role of ceftazidime-avibactam combined with intraventricular polymyxin B as a therapeutic option for CRKP meningitis in children. Further studies are needed to optimize dosing strategies and evaluate long-term safety in the paediatric population.
METHODS: A 9-y-old child with severe traumatic brain injury and multiple prior neurosurgical procedures developed CRKP meningitis. After pathogen identification, antimicrobial therapy was switched to CZA plus intraventricular PMB, and the ventriculoperitoneal shunt was externalized. Clinical outcomes, cerebrospinal fluid (CSF) parameters, microbiological clearance, and plasma and CSF concentration of CZA were monitored during treatment.
RESULTS: After CRKP was identified, therapy was adjusted to CZA (62.5 mg/kg every 8 h, administered as a 2-h infusion) plus intraventricular PMB based on susceptibility results. Fever resolved within 3 d of CZA initiation. CSF cultures became negative, and CSF parameters gradually normalized. Neurological status improved, and the patient was transferred to a rehabilitation facility. Pharmacokinetic analysis showed blood-brain barrier penetration rates of 19.4% for ceftazidime and 29.9% for avibactam.
CONCLUSIONS: This report adds to the limited pharmacokinetic/pharmacodynamic (PK/PD) evidence for ceftazidime-avibactam in paediatric CNS infections. It also supports the potential role of ceftazidime-avibactam combined with intraventricular polymyxin B as a therapeutic option for CRKP meningitis in children. Further studies are needed to optimize dosing strategies and evaluate long-term safety in the paediatric population.